An oral concurrent session at SMFM’s 42nd Annual Pregnancy Meeting highlighted an analysis of pregnancy outcomes after optimal prenatal opioid use disorder care.
The Illinois Perinatal Quality Collaborative—a statewide network of hospital teams, perinatal clinicians, public health leaders and policymakers dedicated to improving obstetric and neonatal care—launched the Mothers and Newborns Affected by Opioids (MNO) initiative in 2018. A primary goal of the MNO initiative is to increase the use of medication-assisted treatment (MAT) and recovery treatment services (RTS) in pregnant patients with opioid use disorder (OUD).
Ann Borders, MD, MPH, MSc, clinical associate professor and ILPQC executive director, Northshore University Health System, Evanston Hospital, Evanston, Illinois, led a research team to determine associations between prenatal MAT and RST and pregnancy outcomes. She presented the findings at the Society for Maternal-Fetal Medicine’s 42nd Annual Pregnancy Meeting.1
Borders’ primary goal was to see what—if any—impact prenatal MAT and RTS provision had on preterm birth and higher gestational age. From 92 hospitals across Illinois, monthly key measures were reported for 2,095 patients with OUD at delivery from July 2018 to December 2020.
Researchers found that prenatal RTS and MAT, when received independently or together, were associated with lower odds of preterm birth and higher gestational age, regardless of race/ethnicity and maternal age. During the analysis period, the ILPQC facilitated collaborative learning opportunities, rapid-response data and quality improvement support, and the rates of patients receiving MAT and RTS increased from 41% to 78% and from 48% to 67%, respectively. In a subgroup analysis of patients only receiving prenatal care, researchers still found significant association between lower preterm birth and RTS or both MAT and RTS.
Reference
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Expert consensus sheds light on diagnosis and management of vasa previa
December 5th 2024A recent review established guidelines for prenatal diagnosis and care of vasa previa, outlining its definition, screening and diagnosis, management, and timing of delivery in asymptomatic patients.
Read More
Cesarean delivery reduces mortality risk in preterm breech births
December 2nd 2024In a recent study, infants born very preterm or extremely preterm had reduced odds of mortality when cesarean delivery was chosen as the mode of delivery, without a notable increase in any morbidity risk.
Read More
Reduced subsequent births reported after severe maternal morbidity
November 26th 2024Women experiencing severe maternal morbidity during their first pregnancy face significantly lower odds of subsequent births, emphasizing the need for personalized reproductive counseling and ongoing monitoring.
Read More